1h Free Analyst Time
The multiple myeloma drugs market is forecasted to grow by USD 7.94 billion during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the multiple myeloma drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing incidence of multiple myeloma, growing demand for biological therapies, and strong adoption rate.
The multiple myeloma drugs market is segmented as below:
By Therapy
- Targeted therapy
- Biologic therapy
- Chemotherapy
- Others
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- E-pharmacy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the multiple myeloma drugs market covers the following areas:
- Multiple myeloma drugs market sizing
- Multiple myeloma drugs market forecast
- Multiple myeloma drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global multiple myeloma drugs market: Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., PharmaMar SA, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is emergence of nanomedicine platform."
According to the report, one of the major drivers for this market is the growing incidence of multiple myeloma.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Bristol Myers Squibb Co.
- Cipla Inc.
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Fresenius SE and Co. KGaA
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- PharmaMar SA
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
